CRIS Current Research Information System

FREGA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.527
NA - Nord America 3.429
EU - Europa 2.149
AF - Africa 232
SA - Sud America 146
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.488
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.367
VN - Vietnam 988
SG - Singapore 967
CN - Cina 855
IT - Italia 559
GB - Regno Unito 314
SE - Svezia 286
DE - Germania 225
HK - Hong Kong 200
IN - India 131
KR - Corea 130
FR - Francia 125
IE - Irlanda 110
CH - Svizzera 103
NL - Olanda 100
BR - Brasile 97
FI - Finlandia 78
RU - Federazione Russa 76
CI - Costa d'Avorio 70
SC - Seychelles 58
CA - Canada 37
JP - Giappone 37
BD - Bangladesh 31
TG - Togo 31
NG - Nigeria 29
PH - Filippine 27
ZA - Sudafrica 26
ID - Indonesia 24
BG - Bulgaria 22
AT - Austria 21
JO - Giordania 21
UA - Ucraina 21
GR - Grecia 19
PL - Polonia 18
EE - Estonia 17
TR - Turchia 17
AR - Argentina 15
BE - Belgio 15
IQ - Iraq 14
TH - Thailandia 13
TW - Taiwan 13
MX - Messico 12
ES - Italia 11
PK - Pakistan 11
CL - Cile 10
PS - Palestinian Territory 10
EC - Ecuador 9
MY - Malesia 8
CO - Colombia 6
IR - Iran 6
SA - Arabia Saudita 6
NI - Nicaragua 5
PT - Portogallo 5
RO - Romania 5
TN - Tunisia 5
DK - Danimarca 4
MA - Marocco 4
KZ - Kazakistan 3
LT - Lituania 3
PY - Paraguay 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
BO - Bolivia 2
EG - Egitto 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
PA - Panama 2
SI - Slovenia 2
UG - Uganda 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
CG - Congo 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GE - Georgia 1
GI - Gibilterra 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 9.487
Salva come PNG Salva come JPEG
Città #
Singapore 696
Dallas 407
Ashburn 373
Hefei 287
Chandler 285
Southend 249
San Jose 212
Ho Chi Minh City 205
Hong Kong 190
Dong Ket 188
Fairfield 182
Hanoi 174
Santa Clara 131
Seoul 112
Dublin 110
Houston 108
Princeton 97
Bologna 95
Bern 94
Beijing 88
Wilmington 80
Woodbridge 80
Seattle 73
Abidjan 70
New York 69
Helsinki 67
Boardman 66
Council Bluffs 59
Lauterbourg 58
Los Angeles 56
Cambridge 55
Ann Arbor 53
Rome 51
Frankfurt am Main 42
Milan 34
Berlin 31
Haiphong 31
Lomé 31
Tokyo 30
Nanjing 29
Bengaluru 27
Da Nang 27
Turin 27
Redondo Beach 26
Westminster 25
Redmond 23
Sofia 22
Amman 21
Buffalo 20
London 20
Jakarta 19
San Diego 19
Abeokuta 18
Florence 18
São Paulo 17
Padova 14
Tongling 14
Brussels 13
Ravenna 13
Can Tho 12
Jinan 12
Medford 12
Munich 12
Orem 12
Shanghai 12
Toronto 12
Warsaw 12
Guangzhou 11
Montreal 11
Phoenix 11
Chicago 10
Ninh Bình 10
Hải Dương 9
Vienna 9
Wuhan 9
Zhengzhou 9
Chennai 8
Denver 8
Groningen 8
Halhul 8
Istanbul 8
Mexico City 8
Olalla 8
Saint Petersburg 8
Yubileyny 8
Amsterdam 7
Biên Hòa 7
Bremen 7
Lappeenranta 7
Poplar 7
San Francisco 7
Tianjin 7
Torino 7
Bari 6
Bến Tre 6
Changsha 6
Forlì 6
Hebei 6
Nuremberg 6
Portsmouth 6
Totale 6.086
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 455
Adjuvant treatment in biliary tract cancer 343
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 309
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 296
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 281
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 247
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 247
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 239
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 239
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 227
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 217
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 216
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 216
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 215
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 207
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 205
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 201
Bone metastases in biliary cancers: A multicenter retrospective survey 199
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 199
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 196
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 193
In Reply 191
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study 188
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 185
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 178
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 177
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 175
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 175
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 170
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 167
Chemotherapy in Patients with Advanced Cholangiocarcinoma 163
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 159
Hacking pancreatic cancer: Present and future of personalized medicine 159
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 139
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 135
Experimental HER2- targeted therapies for biliary tract cancer 127
BAP1 in solid tumors 126
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 125
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 124
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 119
NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report 117
Histological and imaging features of myoepithelial carcinoma of the bone and soft tissue 115
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 109
Microbiota: Overview and implication in immunotherapy-based cancer treatments 108
Nivolumab: an investigational agent for the treatment of biliary tract cancer 101
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms 98
A reduction in tumor volume exceeding 65% predicts a good histological response to neoadjuvant chemotherapy in patients with Ewing sarcoma 89
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 87
The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies? 87
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 84
The human microbiomes in pancreatic cancer: Towards evidence-based manipulation strategies? 81
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 77
Second-line FOLFOX chemotherapy for advanced biliary tract cancer 77
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications 49
Comparison of histological response across patients with Ewing sarcoma treated with preoperative chemotherapy with or without preoperative radiotherapy 35
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 32
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 27
Totale 9.709
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.672
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.672
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021273 0 0 0 0 0 0 0 0 0 0 19 254
2021/2022920 57 29 35 68 61 33 22 54 133 85 198 145
2022/20231.265 122 169 60 133 96 96 36 79 197 47 84 146
2023/2024399 63 55 26 39 22 65 18 29 3 28 31 20
2024/20251.580 92 208 146 109 170 62 93 82 41 117 128 332
2025/20264.085 406 501 653 319 366 200 374 136 706 299 125 0
Totale 9.709